Methylthioninium chloride controlled-release tablet - Cosmo

Drug Profile

Methylthioninium chloride controlled-release tablet - Cosmo

Alternative Names: CB-17-01; Methylene blue delayed-release - Cosmo; Methylene blue MMX®; Methylene blue tablet - Cosmo

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Diagnostic agents; Dimethylamines; Phenothiazines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 03 Mar 2017 Phase-III development is ongoing in Belgium, Canada, Germany, Italy, Lithuania, Netherlands, USA, United Kingdom
  • 01 Oct 2016 Cosmo Pharmaceuticals completes a phase III trial in Colorectal cancer (Diagnosis, In adults, In the elderly) in USA, Canada, Belgium, Germany, Italy, Lithuania, Netherlands and United Kingdom (PO) (NCT01694966)
  • 01 Dec 2014 Cosmo completes a phase II trial in Colorectal cancer diagnosis in Italy (NCT02295774)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top